Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Langenbucher

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Nature|July 5, 2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.
Cell|June 4, 2019
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic CancerMatteo Ligorio, Srinjoy Sil, Jose Malagon-Lopez, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Nature|July 5, 2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.
Cell|June 4, 2019
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic CancerMatteo Ligorio, Srinjoy Sil, Jose Malagon-Lopez, et al.
Pageof 3